Rosetta Genomics Receives Key U.S. Patent Allowance for its Cancer of Origin Diagnostic Assay

Covers method of identifying the tissue of origin from a tissue sample through measuring the expression levels of 64 microRNAs

PRINCETON, N.J. & REHOVOT, Israel--- Rosetta Genomics Ltd. (ROSG), a leading developer and provider of microRNA-based assays, FISH testing and other molecular diagnostics, announces receipt of a Notice of Allowance for U.S. Patent Application No. 13/856,190, entitled, “Methods and materials for classification of tissue of origin of tumor samples.”

Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer

-- TRXE-009 distinguished by ability to kill chemo-resistant adult and paediatric brain cancer cells
-- Studies to optimize delivery of TRXE-009 to brain cancer tissue

SYDNEY, April 17, 2015 -- US-Australian drug discovery company, Novogen, today announced that it had signed a Memorandum of Understanding with the Feinstein Institute for Medical Research ('Feinstein Institute') of New York to collaborate with the objective of developing effective treatments for brain cancers.

The collaboration brings together the drug discovery expertise of Novogen and the preclinical and clinical expertise of the Feinstein Institute in neurosciences and oncology.

FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis

LA JOLLA, Calif., April 16, 2015  -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-001 (tipelukast) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.

Celsion Announces Positive Interim Data from its Phase 2 DIGNITY Study in Breast Cancer

ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Highly Refractory Patients --- Company to Initiate Euro-DIGNITY Trial This Quarter --- European Early Access Program Set to Launch This Month

LAWRENCEVILLE, N.J., April 15, 2015 -- Celsion Corporation (CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in recurrent chest wall (RCW) breast cancer.  The trial is designed to enroll up to 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 16 patients enrolled and treated, 12 were eligible for evaluation of efficacy. Based on data available to date, 67% of patients experienced a clinical benefit of their highly refractory disease with a local response rate of 58% observed in the 12 evaluable patients, notably 5 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD).  The Company remains on track to complete enrollment in the study in the third quarter of 2015.